Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer

• Publication date

  2006-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/cncr.22208PMID 16955506
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer Statistics, 2006

  2006cited by this paper
• Treatment of advanced non-small cell lung cancer.

  2006cited by this paper
• Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung

  2006cited by this paper
• Vascular Endothelial Growth Factor Messenger RNA Expression Level Is Preserved in Liver Metastases Compared with Corresponding Primary Colorectal Cancer

  2006cited by this paper
• Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth.

  2006cited by this paper
• Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer.

  2005cited by this paper
• Thymidylate synthase structure, function and implication in drug discovery.

  2005cited by this paper
• Cancer incidence and mortality in Europe, 2004.

  2005cited by this paper
• Cathepsin K Is Selectively Expressed in the Stroma of Lung Adenocarcinoma but Not in Bronchioloalveolar Carcinoma

  2005cited by this paper
• Cancer incidence and mortality in Europe

  2005cited by this paper
• A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)--the 4th study.

  2005cited by this paper
• Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  2004influential reference
• A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.

  2004cited by this paper
• Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer.

  2004cited by this paper
• Uracil/Tegafur Plus Cisplatin with Concurrent Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer

  2004cited by this paper
• Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC).

  2004cited by this paper
• Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer.

  2004cited by this paper
• Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.

  2003cited by this paper
• Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

  2003cited by this paper
• Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives

  2002cited by this paper
• Pemetrexed combination therapy in the treatment of non-small cell lung cancer.

  2002cited by this paper
• Pemetrexed in the treatment of selected solid tumors.

  2002cited by this paper
• Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer.

  2002cited by this paper
• Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung.

  2002cited by this paper
• Real-Time Quantitative PCR

  2002cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Pemetrexed disodium (Eli Lilly).

  2001cited by this paper
• ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

  2001cited by this paper
• Novel combination chemotherapy in the treatment of non-small cell lung cancer

  2000cited by this paper
• Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence

  2000cited by this paper
• Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer.

  1999cited by this paper
• Prognostic Value of p53, Glutathione S-Transferase π, and Thymidylate Synthase for Neoadjuvant Cisplatin-based Chemotherapy in Head and Neck Cancer

  1999cited by this paper
• Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.

  1999cited by this paper
• p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival.

  1998cited by this paper
• Real time quantitative PCR.

  1996cited by this paper
• A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small-cell lung cancer: a Mid-Atlantic Oncology Program study.

  1991cited by this paper
• Cancer statistics

  1989cited by this paper

• Significance of TYMS Polymorphism rs3819102 as a Prognostic Marker for Nonsmoking Lung Cancer Patients of the Han Ethnicity in China

  2025cites this paper
• Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.

  2025cites this paper
• Efficacy and safety of taxane versus gemcitabine for advanced stage lung squamous cell carcinoma in global EHR-based retrospective cohorts: A pairwise propensity score-matched comparison.

  2025cites this paper
• The Impact of the Histologic Types of Lung Cancer on CBC-Derived Inflammatory Markers—Current Knowledge and Future Perspectives

  2025cites this paper
• Variation in CBC-Derived Inflammatory Biomarkers Across Histologic Subtypes of Lung Cancer: Can Histology Guide Clinical Management?

  2025cites this paper
• Histology-driven hypofractionated radiation therapy schemes for early-stage lung adenocarcinoma and squamous cell carcinoma.

  2024cites this paper
• SIRPG promotes lung squamous cell carcinoma pathogenesis via M1 macrophages: a multi-omics study integrating data and Mendelian randomization

  2024cites this paper
• Prognostic Value of Chromatin Structure Typing in Early-Stage Non-Small Cell Lung Cancer

  2023cites this paper
• Comparison of Recurrence Patterns between Adenocarcinoma and Squamous Cell Carcinoma after Stereotactic Body Radiotherapy for Early-Stage Lung Cancer

  2023cites this paper
• Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122).

  2023cites this paper
• Phase II trial of daily S‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101

  2023cites this paper
• Polymorphism in Thymidylate Synthase Gene Predicts Survival and Toxicity in North Indian Lung Cancer Patients Undergoing Platinum-Based Doublet Chemotherapy.

  2022cites this paper
• Methionine synthase is essential for cancer cell proliferation in physiological folate environments

  2021cites this paper
• Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer

  2021cites this paper
• International Tailored Chemotherapy Adjuvant (ITACA) Trial, a Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in completely Resected Stage II-IIIA Non-Small Cell Lung Cancer.

  2021cites this paper
• Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma

  2021cites this paper
• Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study

  2021cites this paper
• Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer

  2020cites this paper
• Methionine synthase is essential for cancer cell proliferation in physiological folate environments

  2020cites this paper
• Clinical implications of lung neuroendocrine neoplasm classification

  2020cites this paper
• Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase–Low Squamous Cell Lung Cancer

  2020cites this paper
• Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review

  2020cites this paper
• A non-proliferative role of pyrimidine metabolism in cancer

  2020cites this paper
• Novel Multitarget Therapies for Lung Cancer and Respiratory Disease

  2020cites this paper
• Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement

  2019cites this paper
• Cáncer de pulmón de célula no pequeña metastásico

  2019cites this paper
• Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients

  2019cites this paper
• Phase I/II Study of Docetaxel and S-1 in Previously-Treated Patients with Advanced Non-Small Cell Lung Cancer: LOGIK0408

  2019cites this paper
• Integrated Bioinformatics Analysis of Hub Genes and Pathways in Anaplastic Thyroid Carcinomas

  2019cites this paper
• [Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis].

  2019cites this paper
• New options for combination therapy for advanced non-squamous NSCLC

  2019cites this paper
• ACTH-producing tumorlets and carcinoids of the lung: clinico-pathologic study of 63 cases and review of the literature

  2019cites this paper
• Prediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profiles

  2019cites this paper
• A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer.

  2019cites this paper
• Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers

  2019cites this paper
• Polymorphism rs3819102 in thymidylate synthase and environmental factors: effects on lung cancer in Chinese population.

  2019cites this paper
• Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach

  2018cites this paper
• 44 – Frontline Systemic Therapy Options in Nonsmall Cell Lung Cancer

  2018cites this paper
• Inhibition of MDM 2 via Nutlin-3 A : A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM 2-Induced Inactivation of Wild-Type P 53

  2018cites this paper
• Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview.

  2018cites this paper
• Adjuvant and Neoadjuvant Chemotherapy for Early-Stage Nonsmall Cell Lung Cancer

  2018cites this paper
• Thymidylate synthase maintains the de-differentiated state of aggressive breast cancers

  2018cites this paper
• Efficacy and safety of pemetrexed and cisplatin chemotherapy as first line in advanced stage of lung adenocarcinoma.

  2018cites this paper
• A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma

  2018cites this paper
• Are We Ready for Histology-Driven Stereotactic Ablative Radiotherapy?

  2018cites this paper
• Chemotherapy for Lung Cancer in the Era of Personalized Medicine

  2018cites this paper
• Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53

  2018cites this paper
• Perioperative chemotherapy with pemetrexed and cisplatin for pulmonary large-cell neuroendocrine carcinoma: a case report and literature review

  2018cites this paper
• Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma

  2017cites this paper
• Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non–Small‐cell Lung Cancer

  2017cites this paper
• Developments in pharmacotherapy for treating metastatic non-small cell lung cancer

  2017cites this paper
• New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib

  2017cites this paper
• Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First‐line Treatment of Nonsquamous Non–Small‐cell Lung Cancer: A TRAIL Trial

  2017cites this paper
• Adenocarcinoma of the lung: an exploration of the relationships between histopathology, molecular pathology and inflammatory markers and their relationship to patient outcomes

  2017influential citation
• Thymidylate synthase is functionally associated with ZEB1 and contributes to the epithelial‐to‐mesenchymal transition of cancer cells

  2017cites this paper
• Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression

  2017cites this paper
• New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib

  2017cites this paper
• Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients.

  2017cites this paper
• A Randomized Phase III Study of Docetaxel plus Cisplatin versus Pemetrexed plus Cisplatin as First-line Treatment for Non-squamous Non-small Cell Lung Cancer: A TRAIL Trial

  2017cites this paper
• Personalized Therapy of Non-small Cell Lung Cancer (NSCLC).

  2016cites this paper
• Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines

  2016cites this paper
• Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement

  2016cites this paper
• Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer

  2016cites this paper
• Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

  2016cites this paper
• Resistance to Therapy.

  2016cites this paper
• Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome

  2016cites this paper
• Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer

  2016cites this paper
• On the pharmacogenetics of non-small cell lung cancer treatment

  2016cites this paper
• Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression

  2016cites this paper
• Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer.

  2016cites this paper
• Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

  2016cites this paper
• Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in Non-small Cell Lung Cancer.

  2016cites this paper
• Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care?

  2015cites this paper
• Variation in the expression levels of predictive chemotherapy biomarkers in histological subtypes of lung adenocarcinoma: an immunohistochemical study of tissue samples.

  2015cites this paper
• Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.

  2015cites this paper
• Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I–III Non-Small Cell Lung Cancer

  2015cites this paper
• Best practice in the treatment of advanced squamous cell lung cancer

  2015cites this paper
• Identifying CDKN3 Gene Expression as a Prognostic Biomarker in Lung Adenocarcinoma via Meta-analysis

  2015cites this paper
• Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer

  2015cites this paper
• Addressing the unmet need in lung cancer: The potential of immuno-oncology.

  2015cites this paper
• Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity

  2015cites this paper
• Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.

  2015cites this paper
• The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients

  2015cites this paper
• Maintenance therapy in non-small cell lung cancer

  2015cites this paper
• Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations

  2015cites this paper
• Superiority of concomitant chemoradiation over sequential chemoradiation in inoperable, locally advanced non-small cell lung cancer: challenges in the selection of appropriate chemotherapy.

  2015cites this paper
• Therapy options for advanced NSCLC

  2015cites this paper
• Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes

  2015cites this paper
• Can we expect progress from targeted therapy of SCLC

  2015cites this paper
• How to Personalize Perioperative Chemotherapy in Early Non-small Cell Lung Cancer?

  2015cites this paper
• The Evolution of Therapies in Non-Small Cell Lung Cancer

  2015cites this paper
• Therapeutic options in advanced squamous cell lung carcinoma

  2015cites this paper
• Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.

  2015cites this paper
• Squamous Non–small Cell Lung Cancer as a Distinct Clinical Entity

  2015cites this paper
• Immunohistochemistry. Expression levels of the TS protein were detected by rabbit monoclonal anti-human thymidylate synthetase antibody

  2014cites this paper
• Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)

  2014cites this paper
• Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.

  2014cites this paper
• ERCC1、RRM1和TS在非小细胞肺癌中的临床意义

  2014cites this paper
• Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC)

  2014influential citation
• Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.

  2014cites this paper